Simvastatin: pharmacological response in experimental hyperfibrinogenaemias

Area of Science:

• Cardiovascular Research
• Pharmacology
• Endothelial Biology

Background:

• Hyperfibrinogenaemia disrupts endothelial haemostatic balance, potentially causing endothelial dysfunction.
• Statins possess anti-inflammatory properties beneficial for injured endothelium.

Purpose of the Study:

• To investigate the pharmacological effects of simvastatin in rats experiencing hyperfibrinogenaemia induced by laparotomies.
• To assess simvastatin's impact on endothelial health and fibrinogen levels in a rodent injury model.

Main Methods:

• Rats underwent multiple injuries (MI) over 30 or 60 days via weekly or bi-weekly laparotomies.
• Simvastatin (0.035 mg/kg) was administered orally at different time points post-injury.
• Blood samples were analyzed for plasmatic fibrinogen (PF) levels, and histological examination of endothelial tissues was performed.

Main Results:

• A statistically significant increase in fibrinogen was observed in untreated injured rats compared to controls (p < 0.001).
• Simvastatin treatment did not significantly alter plasmatic fibrinogen levels compared to controls.
• Untreated injured groups showed endothelial denudation and intima widening, while simvastatin-treated groups exhibited regression of histopathological lesions.

Conclusions:

• Simvastatin treatment led to regression of histopathological lesions in injured rat endothelium.
• The observed benefits may be linked to a reduction in the inflammatory component associated with early atherogenesis.
• Decreased plasmatic fibrinogen levels were noted after simvastatin treatment, potentially contributing to lesion regression.